Loading
A phase 1/2 trial of AST-3424 in hepatocellular carcinoma, run by Ascentawits Pharmaceuticals, Ltd, active and no longer recruiting.
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06239155 by Ascentawits Pharmaceuticals, Ltd, with 51 participants enrolled, started 2019-09-03 and due to reach its primary completion in 2025-11-30. Interventions recorded: AST-3424.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ascentawits Pharmaceuticals and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/